A different approach is necessary with Industrial partners, who are encouraged to view the CSG as a conduit through which to develop and commission their own early/late phase studies.
We are particularly keen to assist with the development of phase I/II studies, especially where there is a requirement for intervention such as arthroscopy or MRI. We can contribute to the design of such studies, and facilitate effective recruitment. We are also keen on studies that, where appropriate, bring a drug that is already being tested or used in another clinical field, to the inflammatory arthritis arena. To this end, key industry representatives are kept abreast of developments in order that they approach the CSG when considering implementing trials of their products. Arthritis Research UK is developing the appropriate policies for managing these important links between academia and industrial partners.